Evidence map›Paper›PMID 35649251›Full record

ReviewAmerican journal of physiology. Cell physiology2022

Defining the versican interactome in lung health and disease.

Fengying Tang, Jourdan E Brune, Mary Y Chang, Stephen R Reeves, William A Altemeier, Charles W Frevert

Open access · greenAbstract readReview
In one paragraph

Review in American journal of physiology. Cell physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Roles of extracellular matrix in lung diseases.Fukushima journal of medical science · 2024
    Review
  10. Article
  11. V3: an enigmatic isoform of the proteoglycan versican.American journal of physiology. Cell physiology · 2023
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fengying TangCenter for Lung Biology, The University of Washington at South Lake Union, Seattle, Washington.ORCID 0000-0002-8964-304X
Jourdan E BruneCenter for Lung Biology, The University of Washington at South Lake Union, Seattle, Washington.ORCID 0000-0002-8552-6022
Mary Y ChangCenter for Lung Biology, The University of Washington at South Lake Union, Seattle, Washington.ORCID 0000-0001-6174-7923
Stephen R ReevesCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington.ORCID 0000-0002-8552-6022
William A AltemeierCenter for Lung Biology, The University of Washington at South Lake Union, Seattle, Washington.ORCID 0000-0001-8860-405X
Charles W FrevertCenter for Lung Biology, The University of Washington at South Lake Union, Seattle, Washington.ORCID 0000-0002-1037-3244
University of Washington · USSeattle Children's Hospital · US

Funding

Regulation of Allergen-Induced Airway Pathophysiology by VersicanR01AI130280 · NIAID · UNIVERSITY OF WASHINGTON · PI FREVERT, CHARLES WAYNE, HALLSTRAND, TEAL S · 2019 to 2023
$3.8M
Impact of versican deficiency on the innate immune response to influenza virusR01AI136468 · NIAID · UNIVERSITY OF WASHINGTON · PI ALTEMEIER, WILLIAM A, FREVERT, CHARLES WAYNE · 2018 to 2022
$3.1M
PDGFR-beta+ stromal cells as critical regulators of immune response to tissue injuryR01HL122895 · NHLBI · UNIVERSITY OF WASHINGTON · PI ALTEMEIER, WILLIAM A · 2015 to 2018
$1.7M
Airway epithelial regulation of fibroblast hyaluronan and versican production in asthmatic airway inflammationK08HL135266 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI REEVES, STEPHEN R · 2017 to 2021
$812k
Role of cannabinoid receptor 1 in lung injury and resolutionR21AI147536 · NIAID · UNIVERSITY OF WASHINGTON · PI ALTEMEIER, WILLIAM A, GHARIB, SINA A · 2019 to 2020
$485k
NHLBI NIH HHS K08 HL135266NHLBI NIH HHS R01 HL122895NIAID NIH HHS R01 AI130280NIAID NIH HHS R01 AI136468NIAID NIH HHS R21 AI147536
6 · The paper itself

Abstract

The extracellular matrix (ECM) imparts critical mechanical and biochemical information to cells in the lungs. Proteoglycans are essential constituents of the ECM and play a crucial role in controlling numerous biological processes, including regulating cellular phenotype and function. Versican, a chondroitin sulfate proteoglycan required for embryonic development, is almost absent from mature, healthy lungs and is reexpressed and accumulates in acute and chronic lung disease. Studies using genetically engineered mice show that the versican-enriched matrix can be pro- or anti-inflammatory depending on the cellular source or disease process studied. The mechanisms whereby versican develops a contextual ECM remain largely unknown. The primary goal of this review is to provide an overview of the interaction of versican with its many binding partners, the "versican interactome," and how through these interactions, versican is an integrator of complex extracellular information. Hopefully, the information provided in this review will be used to develop future studies to determine how versican and its binding partners can develop contextual ECMs that control select biological processes. Although this review focuses on versican and the lungs, what is described can be extended to other proteoglycans, tissues, and organs.

Indexed as

Extracellular MatrixVersicansAnimalsLungMiceVersicansextracellular matrixmicroenvironmentsversican interactome

Identifiers

PMID35649251
PMCPMC9291419
OpenAlexW4281636122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.